The Food and Drug Administration recently authorized the temporary import of hydromorphone hydrochloride injection from Canada to address a critical shortage of the drug, an opioid pain medication. This product is marketed in Canada, and is manufactured in Canada by Sandoz Canada Inc. At this time, no other entity except Hospira is authorized by the FDA to import or distribute Sandoz Hydromorphone Hydrochloride Injection, USP 2 mg/mL ampules in the U.S. See the letter to health care providers for more details. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services today released an updated tool for viewing and comparing opioid prescribing rates over time and across regions.
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic last week held a webinar on the work it will undertake over the…
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., today convened a hearing on “Managing Pain During the Opioid Crisis”…
Headline
The Centers for Medicare…
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…